Smith MR - Search Results

1

A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases.

Lee RJ, Saylor PJ, Michaelson MD, Rothenberg SM, Smas ME, Miyamoto DT, Gurski CA, Xie W, Maheswaran S, Haber DA, Goldin JG, Smith MR. Lee RJ, et al. Among authors: smith mr. Clin Cancer Res. 2013 Jun 1;19(11):3088-94. doi: 10.1158/1078-0432.CCR-13-0319. Epub 2013 Apr 3. Clin Cancer Res. 2013. PMID: 23553848 Free PMC article.

2

Selective aromatase inhibition for patients with androgen-independent prostate carcinoma.

Smith MR, Kaufman D, George D, Oh WK, Kazanis M, Manola J, Kantoff PW. Smith MR, et al. Cancer. 2002 Nov 1;95(9):1864-8. doi: 10.1002/cncr.10844. Cancer. 2002. PMID: 12404279 Free article. Clinical Trial.

3

Diagnosis and management of treatment-related osteoporosis in men with prostate carcinoma.

Smith MR. Smith MR. Cancer. 2003 Feb 1;97(3 Suppl):789-95. doi: 10.1002/cncr.11149. Cancer. 2003. PMID: 12548577 Free article. Review.

4

Cross-sectional study of bone turnover during bicalutamide monotherapy for prostate cancer.

Smith MR, Fallon MA, Goode MJ. Smith MR, et al. Urology. 2003 Jan;61(1):127-31. doi: 10.1016/s0090-4295(02)02006-x. Urology. 2003. PMID: 12559282

5

Prostate cancer: metastatic.

Michaelson MD, Talcott JA, Smith MR. Michaelson MD, et al. Among authors: smith mr. Clin Evid. 2002 Dec;(8):881-90. Clin Evid. 2002. Update in: Clin Evid. 2003 Dec;(10):1012-22. PMID: 12603918 Updated. Review. No abstract available.

6

The role of bisphosphonates in the management of metastatic prostate cancer.

Michaelson MD, Smith MR. Michaelson MD, et al. Among authors: smith mr. Curr Oncol Rep. 2003 May;5(3):245-9. doi: 10.1007/s11912-003-0117-4. Curr Oncol Rep. 2003. PMID: 12667423 Review.

7

Genitourinary malignancies.

Michaelson MD, Smith MR. Michaelson MD, et al. Among authors: smith mr. Cancer Chemother Biol Response Modif. 2002;20:471-91. Cancer Chemother Biol Response Modif. 2002. PMID: 12703221 Review. No abstract available.

8

Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.

Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N. Smith MR, et al. J Urol. 2003 Jun;169(6):2008-12. doi: 10.1097/01.ju.0000063820.94994.95. J Urol. 2003. PMID: 12771706 Clinical Trial.

9

Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up.

Oh WK, Manola J, Bittmann L, Brufsky A, Kaplan ID, Smith MR, Kaufman DS, Kantoff PW. Oh WK, et al. Among authors: smith mr. Urology. 2003 Jul;62(1):99-104. doi: 10.1016/s0090-4295(03)00145-6. Urology. 2003. PMID: 12837431 Clinical Trial.

10

Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer.

Small EJ, Smith MR, Seaman JJ, Petrone S, Kowalski MO. Small EJ, et al. Among authors: smith mr. J Clin Oncol. 2003 Dec 1;21(23):4277-84. doi: 10.1200/JCO.2003.05.147. Epub 2003 Oct 27. J Clin Oncol. 2003. PMID: 14581438 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,177 results

Search Page

Filters